KR19990067080A - 특정 뉴클레오티드 서열의 검출방법 및 조성물 - Google Patents
특정 뉴클레오티드 서열의 검출방법 및 조성물 Download PDFInfo
- Publication number
- KR19990067080A KR19990067080A KR1019980703020A KR19980703020A KR19990067080A KR 19990067080 A KR19990067080 A KR 19990067080A KR 1019980703020 A KR1019980703020 A KR 1019980703020A KR 19980703020 A KR19980703020 A KR 19980703020A KR 19990067080 A KR19990067080 A KR 19990067080A
- Authority
- KR
- South Korea
- Prior art keywords
- nucleic acid
- pnas
- dna
- acid sequence
- target
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract description 182
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims abstract description 72
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 156
- 230000001681 protective effect Effects 0.000 claims abstract description 37
- 102000039446 nucleic acids Human genes 0.000 claims description 72
- 108020004707 nucleic acids Proteins 0.000 claims description 72
- 238000001514 detection method Methods 0.000 claims description 59
- 238000009396 hybridization Methods 0.000 claims description 47
- 101710163270 Nuclease Proteins 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 230000000813 microbial effect Effects 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 230000003612 virological effect Effects 0.000 claims 4
- 108020004414 DNA Proteins 0.000 abstract description 135
- 238000003556 assay Methods 0.000 abstract description 29
- 230000008569 process Effects 0.000 abstract description 17
- 230000035945 sensitivity Effects 0.000 abstract description 11
- 238000012360 testing method Methods 0.000 abstract description 10
- 230000004544 DNA amplification Effects 0.000 abstract description 3
- 239000000523 sample Substances 0.000 description 129
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 67
- 230000015572 biosynthetic process Effects 0.000 description 31
- 238000003199 nucleic acid amplification method Methods 0.000 description 31
- 230000003321 amplification Effects 0.000 description 30
- 102000004190 Enzymes Human genes 0.000 description 29
- 108090000790 Enzymes Proteins 0.000 description 29
- 108091034117 Oligonucleotide Proteins 0.000 description 27
- 108091093037 Peptide nucleic acid Proteins 0.000 description 24
- 239000011324 bead Substances 0.000 description 22
- 230000000295 complement effect Effects 0.000 description 21
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 239000000872 buffer Substances 0.000 description 18
- 238000003752 polymerase chain reaction Methods 0.000 description 18
- 230000004224 protection Effects 0.000 description 16
- 239000000758 substrate Substances 0.000 description 16
- 102000053602 DNA Human genes 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 10
- 230000029087 digestion Effects 0.000 description 10
- 244000052769 pathogen Species 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- 108010042407 Endonucleases Proteins 0.000 description 8
- 239000003184 complementary RNA Substances 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 7
- 108020004394 Complementary RNA Proteins 0.000 description 7
- 239000004971 Cross linker Substances 0.000 description 7
- 102000004533 Endonucleases Human genes 0.000 description 7
- 208000031886 HIV Infections Diseases 0.000 description 7
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 239000002751 oligonucleotide probe Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 108060002716 Exonuclease Proteins 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 102000013165 exonuclease Human genes 0.000 description 6
- 238000000198 fluorescence anisotropy Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 108020005029 5' Flanking Region Proteins 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 5
- 208000026350 Inborn Genetic disease Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 235000020958 biotin Nutrition 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 108020003215 DNA Probes Proteins 0.000 description 4
- 239000003298 DNA probe Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- 238000010804 cDNA synthesis Methods 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000007385 chemical modification Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000006862 enzymatic digestion Effects 0.000 description 4
- 208000016361 genetic disease Diseases 0.000 description 4
- 239000006249 magnetic particle Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 238000000053 physical method Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 241001227713 Chiron Species 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102100031780 Endonuclease Human genes 0.000 description 3
- 241001534160 Escherichia virus Qbeta Species 0.000 description 3
- 208000037357 HIV infectious disease Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 101710137500 T7 RNA polymerase Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 229910000266 aqualite Inorganic materials 0.000 description 3
- 239000010836 blood and blood product Substances 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 238000012252 genetic analysis Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- 244000052637 human pathogen Species 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 108010047357 Luminescent Proteins Proteins 0.000 description 2
- 102000006830 Luminescent Proteins Human genes 0.000 description 2
- 208000016604 Lyme disease Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108020004518 RNA Probes Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 239000003391 RNA probe Substances 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 238000012951 Remeasurement Methods 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 244000037640 animal pathogen Species 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000010460 detection of virus Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000012631 diagnostic technique Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 244000053095 fungal pathogen Species 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- -1 magnesium Chemical class 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 244000000003 plant pathogen Species 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 125000006853 reporter group Chemical group 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- HERSSAVMHCMYSQ-UHFFFAOYSA-N 1,8-diazacyclotetradecane-2,9-dione Chemical compound O=C1CCCCCNC(=O)CCCCCN1 HERSSAVMHCMYSQ-UHFFFAOYSA-N 0.000 description 1
- BVTVLEZDVMAWPR-UHFFFAOYSA-N 1h-pyrrolo[2,3-a]acridine Chemical class C1=CC=CC2=CC3=C(NC=C4)C4=CC=C3N=C21 BVTVLEZDVMAWPR-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- FFKUHGONCHRHPE-UHFFFAOYSA-N 5-methyl-1h-pyrimidine-2,4-dione;7h-purin-6-amine Chemical compound CC1=CNC(=O)NC1=O.NC1=NC=NC2=C1NC=N2 FFKUHGONCHRHPE-UHFFFAOYSA-N 0.000 description 1
- LUCHPKXVUGJYGU-XLPZGREQSA-N 5-methyl-2'-deoxycytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 LUCHPKXVUGJYGU-XLPZGREQSA-N 0.000 description 1
- PJHMNWIITGYZDY-UHFFFAOYSA-N 6-amino-1h-pyrimidin-2-one;guanidine Chemical compound NC(N)=N.NC=1C=CNC(=O)N=1 PJHMNWIITGYZDY-UHFFFAOYSA-N 0.000 description 1
- IJIJGGQVAFACNF-RVXOMBSCSA-N 6-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-methylpurin-8-one Chemical compound O=C1N=C2C(C)(N)N=CN=C2N1[C@H]1C[C@H](O)[C@@H](CO)O1 IJIJGGQVAFACNF-RVXOMBSCSA-N 0.000 description 1
- KBRISHLGLPXESO-UHFFFAOYSA-N 7h-purine;pyrimidine Chemical compound C1=CN=CN=C1.C1=CN=CN=C1.C1=NC=C2NC=NC2=N1 KBRISHLGLPXESO-UHFFFAOYSA-N 0.000 description 1
- VCPXMKYSHVGGJL-UHFFFAOYSA-N 7h-purine;pyrimidine Chemical compound C1=CN=CN=C1.C1=NC=C2NC=NC2=N1.C1=NC=C2NC=NC2=N1 VCPXMKYSHVGGJL-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000223848 Babesia microti Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical group OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 230000028937 DNA protection Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- BVTJGGGYKAMDBN-UHFFFAOYSA-N Dioxetane Chemical class C1COO1 BVTJGGGYKAMDBN-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000908713 Homo sapiens Dihydrofolate reductase Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108700020474 Penicillin-Binding Proteins Proteins 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108010053210 Phycocyanin Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000001218 Rec A Recombinases Human genes 0.000 description 1
- 108010055016 Rec A Recombinases Proteins 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108091061763 Triple-stranded DNA Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000726445 Viroids Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000980 acid dye Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000007801 affinity label Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000013142 basic testing Methods 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- YXVFYQXJAXKLAK-UHFFFAOYSA-N biphenyl-4-ol Chemical compound C1=CC(O)=CC=C1C1=CC=CC=C1 YXVFYQXJAXKLAK-UHFFFAOYSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 108010002712 deoxyribonuclease II Proteins 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000018732 detection of tumor cell Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002616 endonucleolytic effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000002109 erythrocyte inclusion Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000001730 gamma-ray spectroscopy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000013412 genome amplification Methods 0.000 description 1
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical class N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000007850 in situ PCR Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- ZDWVWKDAWBGPDN-UHFFFAOYSA-O propidium Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 ZDWVWKDAWBGPDN-UHFFFAOYSA-O 0.000 description 1
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical compound CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 244000079416 protozoan pathogen Species 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 208000008864 scrapie Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6839—Triple helix formation or other higher order conformations in hybridisation assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US593895P | 1995-10-27 | 1995-10-27 | |
| US60/005938 | 1995-10-27 | ||
| PCT/US1996/017191 WO1997015691A1 (en) | 1995-10-27 | 1996-10-25 | Methods and compositions for detection of specific nucleotide sequences |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR19990067080A true KR19990067080A (ko) | 1999-08-16 |
Family
ID=21718453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019980703020A Ceased KR19990067080A (ko) | 1995-10-27 | 1996-10-25 | 특정 뉴클레오티드 서열의 검출방법 및 조성물 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US5962225A (https=) |
| EP (1) | EP0864002A4 (https=) |
| JP (1) | JPH11513887A (https=) |
| KR (1) | KR19990067080A (https=) |
| AU (1) | AU730154B2 (https=) |
| CA (1) | CA2235804A1 (https=) |
| MX (1) | MX9803308A (https=) |
| WO (1) | WO1997015691A1 (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11513887A (ja) | 1995-10-27 | 1999-11-30 | ランバーグ，エリオット，アール． | 特定のヌクレオチド配列の検出方法および組成物 |
| US20050069923A1 (en) * | 1996-07-08 | 2005-03-31 | Mullis Kary Banks | Dual bead assays using cleavable spacers and/or ligation to improve specificity and sensitivity including related methods and apparatus |
| AU1523799A (en) * | 1997-11-12 | 1999-05-31 | Cygene, Inc. | Methods and compositions for detection of specific nucleotide sequences |
| WO2000029624A2 (en) * | 1998-11-19 | 2000-05-25 | Cygene, Inc. | Methods and compositions for detection of nucleic acid sequences and signal amplification |
| EP1190100B1 (en) * | 1999-05-20 | 2012-07-25 | Illumina, Inc. | Combinatorial decoding of random nucleic acid arrays |
| JP4824236B2 (ja) * | 1999-07-09 | 2011-11-30 | ジェン−プローブ・インコーポレーテッド | 核酸増幅によるｈｉｖ−１の検出 |
| WO2001032929A1 (en) * | 1999-11-03 | 2001-05-10 | Cygene, Inc. | Methods and compositions for analysis of snps and strs |
| AU2001227913A1 (en) * | 2000-01-13 | 2001-07-24 | Immunivest Corporation | Ferrofluid based arrays |
| GB0008618D0 (en) * | 2000-04-08 | 2000-05-31 | Univ Strathclyde | Analyte detection & apparatus therefor |
| EP1203945B1 (en) * | 2000-10-26 | 2006-12-20 | Agilent Technologies, Inc. (a Delaware corporation) | Microarray |
| EP1921451A3 (en) | 2001-05-22 | 2008-05-28 | Cygene, Inc. | Complement mediated assays for in vivo and in vitro methods |
| US20040029135A1 (en) * | 2001-12-14 | 2004-02-12 | Ramberg Elliot R. | Diagnostic assays for BCWA |
| WO2003065358A2 (en) * | 2002-01-28 | 2003-08-07 | Burstein Technologies, Inc. | Methods and apparatus for logical triggering of an optical bio-disc |
| AU2003209372B2 (en) * | 2002-01-31 | 2009-02-19 | Burstein Technologies, Inc. | Method for triggering through disc grooves and related optical analysis discs and system |
| US7776524B2 (en) | 2002-02-15 | 2010-08-17 | Genzyme Corporation | Methods for analysis of molecular events |
| EP1543155A4 (en) * | 2002-07-17 | 2006-08-16 | Us Genomics Inc | METHOD AND COMPOSITIONS FOR THE ANALYSIS OF POLYMERS USING CHIMERIC TAGS |
| AU2003256814A1 (en) * | 2002-07-26 | 2004-02-16 | Alfa Wasserman, Inc. | Macromolecular protection assay |
| WO2004042362A2 (en) * | 2002-11-04 | 2004-05-21 | Cygene Laboratories, Inc. | Target sequences for the detection of the west nile virus |
| US20040142329A1 (en) * | 2003-01-17 | 2004-07-22 | Ingeneus Corporation | Probe conjugation to increase multiplex binding motif preference |
| JP3923917B2 (ja) * | 2003-03-26 | 2007-06-06 | 株式会社東芝 | ターゲットの製造方法、標的配列検出方法、ターゲットおよび標的配列検出用アッセイキット |
| CA2875478A1 (en) * | 2003-05-13 | 2005-02-24 | Gen-Probe Incorporated | Method and kit for identifying antibiotic-resistant microorganisms |
| WO2006026654A2 (en) | 2004-08-27 | 2006-03-09 | Exact Sciences Corporation | Method for detecting a recombinant event |
| NZ554538A (en) * | 2004-09-24 | 2009-12-24 | Ingeneus Inc | Genomic assay |
| US9109256B2 (en) | 2004-10-27 | 2015-08-18 | Esoterix Genetic Laboratories, Llc | Method for monitoring disease progression or recurrence |
| US9777314B2 (en) | 2005-04-21 | 2017-10-03 | Esoterix Genetic Laboratories, Llc | Analysis of heterogeneous nucleic acid samples |
| WO2006135790A1 (en) * | 2005-06-09 | 2006-12-21 | Bristol-Myers Squibb Company | Methods of identifying and treating individuals exhibiting mutant kit protein |
| US20070202512A1 (en) * | 2005-08-19 | 2007-08-30 | Bristol-Myers Squibb Company | Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof |
| US7855051B2 (en) * | 2005-09-12 | 2010-12-21 | Research & Diagnostic Systems, Inc. | Mycoplasma detection method and composition |
| WO2007056177A2 (en) * | 2005-11-04 | 2007-05-18 | Bristol-Myers Squibb Pharma Company | T315a and f317i mutations of bcr-abl kinase domain |
| WO2007092941A2 (en) * | 2006-02-08 | 2007-08-16 | Oxonica, Inc. | Sers nanotag assays |
| WO2007109527A1 (en) * | 2006-03-17 | 2007-09-27 | Bristol-Myers Squibb Company | Methods of identifying and treating individuals exhibiting mutant bcr/abl kinase polypeptides |
| US7642049B2 (en) | 2006-06-30 | 2010-01-05 | Bristol-Myers Squibb Company | Method for identifying HIV-1 protease inhibitors with reduced metabolic affects through detection of human resistin polymorphisms |
| WO2008052774A2 (en) * | 2006-10-31 | 2008-05-08 | Noxxon Pharma Ag | Methods for detection of a single- or double-stranded nucleic acid molecule |
| US7947447B2 (en) | 2007-01-16 | 2011-05-24 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| US20110020797A1 (en) * | 2007-02-09 | 2011-01-27 | Bristol-Myers Squibb Company | Methods For Identifying Patients With An Increased Likelihood Of Responding To DPP-IV Inhibitors |
| CN101802225B (zh) * | 2007-07-17 | 2013-10-30 | 私募蛋白质体公司 | 检测样品的多元分析 |
| EP2281069A2 (en) | 2008-05-16 | 2011-02-09 | Bristol-Myers Squibb Company | Methods for identifying subjects with an increased likelihood of responding to dpp-iv inhibitors |
| WO2011109642A1 (en) | 2010-03-03 | 2011-09-09 | Somalogic, Inc. | Aptamers to 4-1bb and their use in treating diseases and disorders |
| JP5901610B2 (ja) | 2010-04-12 | 2016-04-13 | ソマロジック・インコーポレーテッド | ５位修飾ピリミジンとその使用 |
| EP3066219B1 (en) * | 2013-11-08 | 2018-12-26 | Ionis Pharmaceuticals, Inc. | Methods for detecting oligonucleotides |
| KR102798620B1 (ko) | 2018-06-07 | 2025-04-22 | 암젠 인크 | 단백질-폴리뉴클레오티드 접합체에 대한 검출 검정 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4775619A (en) * | 1984-10-16 | 1988-10-04 | Chiron Corporation | Polynucleotide determination with selectable cleavage sites |
| US5258506A (en) | 1984-10-16 | 1993-11-02 | Chiron Corporation | Photolabile reagents for incorporation into oligonucleotide chains |
| US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| FR2596773B1 (fr) | 1986-04-04 | 1988-06-24 | Pasteur Institut | Sonde monocatenaire marquee, non radioactive, procede pour sa fabrication et procede de detection d'une sequence nucleotidique determinee a l'aide de cette sonde |
| US5422251A (en) | 1986-11-26 | 1995-06-06 | Princeton University | Triple-stranded nucleic acids |
| US5176996A (en) * | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5273881A (en) * | 1990-05-07 | 1993-12-28 | Daikin Industries, Ltd. | Diagnostic applications of double D-loop formation |
| ATE217906T1 (de) * | 1990-11-09 | 2002-06-15 | Us Gov Health & Human Serv | Methoden zur zielrichtung von dna |
| DE69132765T2 (de) * | 1990-12-24 | 2002-02-21 | Enzo Diagnostics, Inc. | Verfahren zum Nachweis eines Zielpolynukleotids in einer Probe unter Verwendung eines Reagenz, das den Hintergrund verringert, und eine dieses Reagenz enthaltende Zusammensetzung und Kit. |
| US5607924A (en) | 1992-01-21 | 1997-03-04 | Pharmacyclics, Inc. | DNA photocleavage using texaphyrins |
| WO1993018187A1 (en) * | 1992-03-13 | 1993-09-16 | California Institute Of Technology | Triple helix recognition of dna |
| US5583032A (en) | 1992-10-21 | 1996-12-10 | The Cleveland Clinic Foundation And National Institutes Of Health | Method of cleaving specific strands of RNA |
| US5422253A (en) | 1992-12-07 | 1995-06-06 | Wisconsin Alumni Research Foundation | Method of site specific nucleic acid cleavage |
| US5482836A (en) * | 1993-01-14 | 1996-01-09 | The Regents Of The University Of California | DNA purification by triplex-affinity capture and affinity capture electrophoresis |
| US5518901A (en) * | 1993-04-19 | 1996-05-21 | Murtagh; James J. | Methods for adapting nucleic acid for detection, sequencing, and cloning using exonuclease |
| DE4344742A1 (de) * | 1993-06-09 | 1994-12-15 | Boehringer Mannheim Gmbh | Verfahren zur Immobilisierung von Nukleinsäuren |
| US5726297A (en) | 1994-03-18 | 1998-03-10 | Lynx Therapeutics, Inc. | Oligodeoxyribonucleotide N3' P5' phosphoramidates |
| US5599922A (en) | 1994-03-18 | 1997-02-04 | Lynx Therapeutics, Inc. | Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties |
| US5714328A (en) | 1995-06-07 | 1998-02-03 | Board Of Regents, The University Of Texas System | RNA photocleavage using texaphyrins |
| JPH11513887A (ja) | 1995-10-27 | 1999-11-30 | ランバーグ，エリオット，アール． | 特定のヌクレオチド配列の検出方法および組成物 |
| US5834198A (en) | 1996-03-21 | 1998-11-10 | Boehringer Mamnnheim Gmbh | Selective photoinducted flavin-dependent cleavage of RNA at G-U base pairs and kits therefor |
-
1996
- 1996-10-25 JP JP9516836A patent/JPH11513887A/ja not_active Ceased
- 1996-10-25 WO PCT/US1996/017191 patent/WO1997015691A1/en not_active Ceased
- 1996-10-25 AU AU11568/97A patent/AU730154B2/en not_active Ceased
- 1996-10-25 KR KR1019980703020A patent/KR19990067080A/ko not_active Ceased
- 1996-10-25 CA CA002235804A patent/CA2235804A1/en not_active Abandoned
- 1996-10-25 US US08/739,069 patent/US5962225A/en not_active Expired - Fee Related
- 1996-10-25 EP EP96942723A patent/EP0864002A4/en not_active Withdrawn
-
1998
- 1998-04-27 MX MX9803308A patent/MX9803308A/es unknown
-
1999
- 1999-05-17 US US09/313,121 patent/US6100040A/en not_active Expired - Fee Related
-
2000
- 2000-08-07 US US09/633,848 patent/US6458540B1/en not_active Expired - Fee Related
-
2001
- 2001-11-05 US US09/992,128 patent/US20020119475A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2235804A1 (en) | 1997-05-01 |
| US6100040A (en) | 2000-08-08 |
| WO1997015691A1 (en) | 1997-05-01 |
| US5962225A (en) | 1999-10-05 |
| MX9803308A (es) | 1998-11-29 |
| EP0864002A4 (en) | 1999-07-28 |
| JPH11513887A (ja) | 1999-11-30 |
| US6458540B1 (en) | 2002-10-01 |
| US20020119475A1 (en) | 2002-08-29 |
| AU1156897A (en) | 1997-05-15 |
| AU730154B2 (en) | 2001-03-01 |
| EP0864002A1 (en) | 1998-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR19990067080A (ko) | 특정 뉴클레오티드 서열의 검출방법 및 조성물 | |
| KR0145908B1 (ko) | 핵산 증폭 검출방법 | |
| JP4975905B2 (ja) | 複合生物試料における核酸の単工程調製及び検出 | |
| EP0281927B1 (en) | Assay for nucleic acid sequences in a sample | |
| US5082935A (en) | Diagnostic reagents made by attaching cytidine containing nucleic acid probes to amino functionalized solid supports by bisulfite mediated transamination | |
| US5580971A (en) | Fungal detection system based on rRNA probes | |
| JP2002509436A (ja) | メチシリン耐性ブドウ球菌を迅速に検出するための方法 | |
| CA2070632A1 (en) | Use of dna-dependent rna polymerase transcripts as reporter molecules for signal amplification in nucleic acid hybridization assays | |
| JP2011062210A (ja) | 抗生物質耐性微生物を同定するための方法およびキット | |
| EP2557156A1 (en) | Primer and probe for detecting chlamydia trachomatis, and method for detecting chlamydia trachomatis using same | |
| US6274316B1 (en) | Compositions and methods for detecting vancomycin resistant enterococci by cycling probe reactions | |
| JP2547517B2 (ja) | 鳥型結核菌、ミコバクテリウム・イントラセルレアおよびパラ結核菌に対するプローブ | |
| JP2006525809A5 (https=) | ||
| US5968739A (en) | Nucleic acid primers and probes for detecting Legionella pneumophila | |
| JPH05501052A (ja) | 核酸ハイブリッド形成アッセイを使用する細菌の定量 | |
| WO1997044488A2 (en) | Compositions and methods for the detection of mycobacterium kansasii | |
| JP2010536343A (ja) | 薬剤耐性菌検出方法 | |
| US7122314B2 (en) | Methods for detecting vancomycin-resistant microorganisms and compositions therefor | |
| KR102526656B1 (ko) | 핵산 검출 방법 | |
| JP2004525626A (ja) | ｉｎｓｉｔｕハイブリダイゼーションにより歯周病原性細菌を検出するためのオリゴヌクレオチド・プローブ | |
| JP2000342261A (ja) | ブルクホルデリア・セパシアの検出法及び検出用キット | |
| AU1523799A (en) | Methods and compositions for detection of specific nucleotide sequences | |
| US20070166722A1 (en) | Detection mycobacterium | |
| MXPA00000200A (en) | Compositions and methods for detecting vancomycin resistant enterococci by cycling probe reactions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 19980425 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20011025 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20040225 Patent event code: PE09021S01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20040825 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20050412 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20040825 Comment text: Notification of reason for refusal Patent event code: PE06011S01I Patent event date: 20040225 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |